» Articles » PMID: 31885422

Non-SMC Condensin I Complex Subunit D2 and Non-SMC Condensin II Complex Subunit D3 Induces Inflammation the IKK/NF-κB Pathway in Ulcerative Colitis

Overview
Specialty Gastroenterology
Date 2019 Dec 31
PMID 31885422
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Ulcerative colitis (UC) is a chronic, nonspecific intestinal inflammatory disease with undefined pathogenesis. Non-SMC condensin I complex subunit D2 (NCAPD2) and non-SMC condensin II complex subunit D3 (NCAPD3) play pivotal roles in chromosome assembly and segregation during both mitosis and meiosis. To date, there has been no relevant report about the functional role of NCAPD2 and NCAPD3 in UC.

Aim: To determine the level of NCAPD2/3 in intestinal mucosa and explore the mechanisms of NCAPD2/3 in UC.

Methods: Levels of NCAPD2/3 in intestinal tissue were detected in 30 UC patients and 30 healthy individuals with in situ hybridization (ISH). , NCM60 cells were divided into the NC group, model group, si-NCAPD2 group, si-NCAPD3 group and si-NCAPD2+si-NCAPD3 group. Inflammatory cytokines were measured by ELISA, IKK and NF-κB were evaluated by western blot, and IKK nucleation and NF-κB volume were analyzed by immunofluorescence assay.

Results: Compared with expression in healthy individuals, NCAPD2 and NCAPD3 expression in intestinal tissue was significantly upregulated ( < 0.001) in UC patients. Compared with levels in the model group, IL-1β, IL-6 and TNF-α in the si-NCAPD2, si-NCAPD3 and si-NCAPD2+si-NCAPD3 groups were significantly downregulated ( < 0.01). IKK and NF-κB protein expression in the si-NCAPD2, si-NCAPD3 and si-NCAPD2+si-NCAPD3 groups was significantly decreased ( < 0.01). Moreover, IKK nucleation and NF-κB volume were suppressed upon si-NCAPD2, si-NCAPD3 and si-NCAPD2+ si-NCAPD3 transfection.

Conclusion: NCAPD2/3 is highly expressed in the intestinal mucosa of patients with active UC. Overexpression of NCAPD2/3 promotes the release of pro-inflammatory cytokines by modulating the IKK/NF-κB signaling pathway.

Citing Articles

Silencing NCAPD3 Inhibits Tumor Growth and Metastasis in Hepatocellular Carcinoma by Suppressing PI3K-AKT Signalling Pathway.

Lv J, Gan F, Li M, Yin Q Curr Med Sci. 2025; .

PMID: 40029498 DOI: 10.1007/s11596-025-00026-2.


The causal nexus between diverse smoking statuses, potential therapeutic targets, and NSCLC: insights from Mendelian randomization and mediation analysis.

Cao Z, Zhao S, Wu T, Ding H, Tian Z, Sun F Front Oncol. 2024; 14:1438851.

PMID: 39558952 PMC: 11570405. DOI: 10.3389/fonc.2024.1438851.


NCAPD2 augments the tumorigenesis and progression of human liver cancer via the PI3K‑Akt‑mTOR signaling pathway.

Gu J, Huang K, Zhao W, Zheng X, Wu Y, Yan S Int J Mol Med. 2024; 54(4).

PMID: 39092569 PMC: 11315656. DOI: 10.3892/ijmm.2024.5408.


NCAPD2 promotes the malignant progression of oral squamous cell carcinoma via the Wnt/β-catenin pathway.

Ma P, Yu H, Zhu M, Liu L, Cheng L, Han Z Cell Cycle. 2024; 23(5):588-601.

PMID: 38743408 PMC: 11135826. DOI: 10.1080/15384101.2024.2348918.


Non-SMC condensin I complex subunit D2 (NCAPD2) reveals its prognostic and immunologic features in human cancers.

Dong X, Liu T, Li Z, Zhai Y Aging (Albany NY). 2023; 15(14):7237-7257.

PMID: 37498296 PMC: 10415567. DOI: 10.18632/aging.204904.


References
1.
Zhang P, Liu L, Huang J, Shao L, Wang H, Xiong N . Non-SMC condensin I complex, subunit D2 gene polymorphisms are associated with Parkinson's disease: a Han Chinese study. Genome. 2014; 57(5):253-7. DOI: 10.1139/gen-2014-0032. View

2.
Cai D, Yuan M, Frantz D, Melendez P, Hansen L, Lee J . Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med. 2005; 11(2):183-90. PMC: 1440292. DOI: 10.1038/nm1166. View

3.
Schuster A, Homer C, Kemp J, Nickerson K, Deutschman E, Kim Y . Chromosome-associated protein D3 promotes bacterial clearance in human intestinal epithelial cells by repressing expression of amino acid transporters. Gastroenterology. 2015; 148(7):1405-1416.e3. PMC: 4446190. DOI: 10.1053/j.gastro.2015.02.013. View

4.
Rogler G, Biedermann L . Clinical Utility of Biomarkers in IBD. Curr Gastroenterol Rep. 2015; 17(7):26. DOI: 10.1007/s11894-015-0449-x. View

5.
Li R, Shen Q, Wu N, He M, Liu N, Huang J . MiR-145 improves macrophage-mediated inflammation through targeting Arf6. Endocrine. 2018; 60(1):73-82. DOI: 10.1007/s12020-018-1521-8. View